IDH-wildtype glioblastoma

This study tests whether adding niacin (vitamin B3) to standard treatment (radiation and chemotherapy) can help people with newly diagnosed glioblastoma, an aggressive brain cancer. The trial has two phases: first, finding a safe dose of niacin, and second, checking if it improve…

This study tests whether two immunotherapy drugs, ipilimumab and nivolumab, can shrink or slow the growth of recurrent high-grade gliomas (brain tumors) that have a high number of genetic mutations. About 37 adults with recurrent WHO grade 4 glioma will receive these drugs. The g…

This study tests a combination of two drugs (tocilizumab and atezolizumab) plus targeted radiation in people whose glioblastoma brain tumor has returned. The goal is to make the tumor more responsive to the body's immune system. About 59 adults will take part to find the best dos…

This early-phase trial tests adding mycophenolate mofetil, a drug usually used to prevent organ rejection, to standard chemotherapy and radiation for glioblastoma. The goal is to find a safe dose and see if the combination can make tumor cells more sensitive to treatment. About 6…

This early-stage trial is testing a new oral drug called S095035, alone or combined with another drug (TNG462), in 60 adults with advanced solid tumors that have a specific genetic deletion (MTAP). These cancers have not responded to at least one prior treatment. The study aims t…

This early-phase study tests a new treatment for a type of brain cancer (glioblastoma) that has come back after standard therapy. The treatment uses the patient's own immune cells, which are modified in a lab to recognize and attack the cancer. The main goal is to check the safet…

This phase 1 trial is testing whether amivantamab, an antibody drug given by IV, is safe and tolerable for people with high-grade malignant brain tumors like glioblastoma. The study enrolls about 12 patients with recurrent glioblastoma or certain molecular subtypes. Participants …

This early-phase trial tests a drug called WSD0922-FU in 56 people with certain brain cancers (glioblastoma, anaplastic astrocytoma) or lung cancer that has spread to the brain or spinal cord. The drug blocks a protein called EGFR that helps cancers grow, and is designed to reach…

This phase II trial tests whether combining two immunotherapy drugs (INCAGN1876 and INCMGA00012) with targeted radiation can help people with recurrent glioblastoma, an aggressive brain cancer. The 39 participants receive the drugs before and after surgery to remove the tumor, pl…

This study planned to test a new treatment combining CYNK-001 (natural killer cells from donated cord blood) with interleukin-2 in adults whose glioblastoma had returned and could be surgically removed. The goal was to see if this combination was safe and could extend the time be…

This trial tests an implantable ultrasound device that temporarily opens the blood-brain barrier, allowing chemotherapy to reach brain tumors. It includes 57 adults with recurrent glioblastoma who have already tried 1-2 treatments. The goal is to find a safe dose and see if this …

This early-phase trial tests two mRNA vaccines, GV-907 and GV-108, in 9 adults with a specific type of glioblastoma. The goal is to see if the vaccines are safe and can trigger an immune response to prevent the cancer from coming back after standard treatment.

This phase 2 trial tests the drug azeliragon, taken as a capsule, together with radiation therapy for people with a specific type of glioblastoma (a fast-growing brain cancer). The study includes 30 participants whose tumors lack a certain DNA marker (MGMT unmethylated). The goal…

This early-phase trial tests whether adding the drug quisinostat to standard radiation therapy can help control grade 4 glioblastoma, a fast-growing brain cancer. It includes up to 30 adults with either newly-diagnosed or recurrent tumors. Researchers first measure how much drug …

This early-stage study tests a genetically engineered virus (rQNestin34.5v.2) that is injected directly into recurrent brain tumors to see if it is safe and what dose works best. About 62 adults with certain types of brain cancer that have come back or worsened are taking part. T…

This study is not testing a new treatment. Instead, researchers are reviewing medical records from 1000 adults with recurrent malignant gliomas (aggressive brain tumors) to see how well past chemotherapy and targeted therapies worked. The goal is to learn which treatments are lin…

This early-phase trial tests whether fluoxetine, an FDA-approved antidepressant, can increase stress in cell structures called lysosomes to make the chemotherapy drug temozolomide more effective against recurrent brain tumors. Ten participants with recurrent glioma will receive e…